|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Pravastatin#Adult Indications and Dosage]] |
| {{Pravastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to [[hypercholesterolemia]]. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.
| |
| | |
| === Prevention of Cardiovascular Disease===
| |
| | |
| In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), PRAVACHOL (pravastatin sodium) is indicated to:
| |
| | |
| *reduce the risk of [[myocardial infarction]] (MI).
| |
| *reduce the risk of undergoing myocardial [[revascularization]] procedures.
| |
| *reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes.
| |
| | |
| In patients with clinically evident CHD, PRAVACHOL is indicated to:
| |
| | |
| *reduce the risk of total mortality by reducing coronary death.
| |
| *reduce the risk of MI.
| |
| *reduce the risk of undergoing myocardial [[revascularization]] procedures.
| |
| *reduce the risk of [[stroke]] and [[stroke]]/[[transient ischemic attack]] ([[TIA]]).
| |
| *slow the progression of coronary [[atherosclerosis]].
| |
| | |
| ===Hyperlipidemia===
| |
| | |
| PRAVACHOL is indicated:
| |
| | |
| *as an adjunct to diet to reduce elevated total [[cholesterol ]](Total-C), low-density lipoprotein cholesterol (LDL-C), [[apolipoprotein B]] (ApoB), and [[triglyceride]] (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).1
| |
| *as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV).
| |
| *for the treatment of patients with primary [[dysbetalipoproteinemia]] (Fredrickson Type III) who do not respond adequately to diet.
| |
| *as an adjunct to diet and lifestyle modification for treatment of [[heterozygous familial hypercholesterolemia]] (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present:
| |
| 1.LDL-C remains ≥190 mg/dL or
| |
| 2.LDL-C remains ≥160 mg/dL and:
| |
| **there is a positive family history of premature cardiovascular disease (CVD) or
| |
| **two or more other CVD risk factors are present in the patient.
| |
| | |
| ===Limitations of Use===
| |
| | |
| PRAVACHOL has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PRAVACHOL (PRAVASTATIN SODIUM) TABLET [E.R. SQUIBB & SONS, L.L.C.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=897ad8b7-921d-eb02-a61c-3419e662a2da | publisher = | date = | accessdate = 18 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Statins]]
| |
| [[Category:Bristol-Myers Squibb]]
| |
| [[Category:Diols]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Carboxylate esters]]
| |
| [[Category:Naphthalenes]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |